Dioxybenzone
Based on 1 Customer Validation
Dioxybenzone (Benzophenone-8; UV-24) is an organic compound used to block UVB and short-wave UVA (ultraviolet) radiation. Dioxybenzone has orally activity. Dioxybenzone exhibits estrogenic disrupting effect. Dioxybenzone up-regulates inflammatory cytokines. Dioxybenzone can be used for cancer, reproductive system disease and inflammatory disease study.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.86%
- CAS No.: 131-53-3
- 화학식: C14H12O4
- 분자량:244.24
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-B0966R
Dioxybenzone (Standard)
-
HY-121254
GERI-BP002-A
-
HY-W011927
4,4'-Sulfonyldiphenol
-
HY-128387R
2,3-Butanediol (Standard)
-
HY-128387
2,3-Butanediol
-
HY-12444
Y15
-
HY-Y0525
AAPH
-
HY-W011927R
4,4'-Sulfonyldiphenol (Standard)
-
HY-W017132
2,4-PDCA
-
HY-Y0546
Benzophenone
-
HY-W016189
4,4'-Dihydroxybiphenyl
-
HY-W012723
2-Hydroxyethyl methacrylate
Biological Activity
Dioxybenzone (0.1-1 μM, 24-72 h) exhibits estrogenic disrupting effect via increasing the mRNA expressions and production of the growth factors responsible for epithelial proliferation, including Fgfs and Igf-1 in human endometrial stromal cells (HESCs)[2].
Dioxybenzone (0.1-1 μM, 24-72 h) up-regulates the mRNA expressions of inflammatory cytokines especially IL-1β in HESCs[2].
Dioxybenzone (20-600 μM, 24 h) chlorination decreases its UV absorbance and generates cytotoxic product(s) in human diploid fibroblasts (HDFs) [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Dioxybenzone (20-100 mg/kg; i.p.; daily for 3 days) increases mRNA expressions of estrogen signaling and inflammation target genes in mice uterus[2].
Dioxybenzone (20-100 mg/kg; i.p.; daily for 3 days) significantly induces transcriptome aberration involved in cancer, reproductive system disease and inflammatory disease[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immature female ICR mice (17-18 d, 17-19 g)[2]
-
Dosage:20, 100 mg/kg
-
Administration:Intraperitoneal injection (i.p.); daily for 3days
-
Result:Increased mRNA expressions of estrogen signaling and inflammation target genes in mice uterus.
Upregulated mRNA expressions of inflammation genes including S100a8, IL-1β and CXCL2.
The increased expression of Sprr2 genes inferred the abnormal growth of endometrium.
The number of endometrial glands were increased, indicating the abnormal uterus shapes.
-
Animal Model:Female, hairless HOS:HR-1 mice (6 weeks old) (Skin tumors were induced by a single dose of (±)-(E)-4-methyl-2-[-(E)-hydroxyamino]-5-nitro-6-methoxy-3-hexanamide (NOR-1), One week later, 12-Otetradecanoyl-phorbol-13-acetate (TPA) was applied to skin twice weekly for 20 weeks as tumor a promoter)[1]
-
Dosage:0.0025% in drinking water
-
Administration:Oral gavage (p.o.); started one week prior to and stopped one week after tumor initiation through drinking water ad libitum.
-
Result:Inhibited NOR-1-induced, TPA-promoted skin tumors in mice.
Showed in two week delay in skin tumor appearance and significant inhibition of tumor incidence compared to the control group of mice.
Significantly reduced the average number of tumors formed per mouse.
No noticeable difference in body weight gain between the control and test groups.
Chemical Information
-
CAS No. 131-53-3
-
Appearance Solid
-
분자량 244.24
-
화학식 C14H12O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C(OC)C=C1O)C2=CC=CC=C2O
-
Synonyms
Benzophenone-8; UV-24
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
DMSO : ≥ 100 mg/mL (409.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rao GS, et al. Oral chemoprevention of skin cancer in mice by benzophenone sunscreens dioxybenzone and octabenzone in drinking water. Anticancer Res. 2013 Jun;33(6):2535-40. [Content Brief]
[2]. Zhan T, et al. Transcriptome aberration in mice uterus associated with steroid hormone response and inflammation induced by dioxybenzone and its metabolites. Environ Pollut. 2021 Oct 1;286:117294. [Content Brief]
[3]. Sherwood VF, et al. Altered UV absorbance and cytotoxicity of chlorinated sunscreen agents. Cutan Ocul Toxicol. 2012 Dec;31(4):273-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0943 mL | 20.4717 mL | 40.9433 mL | 102.3583 mL |
| 5 mM | 0.8189 mL | 4.0943 mL | 8.1887 mL | 20.4717 mL | |
| 10 mM | 0.4094 mL | 2.0472 mL | 4.0943 mL | 10.2358 mL | |
| 15 mM | 0.2730 mL | 1.3648 mL | 2.7296 mL | 6.8239 mL | |
| 20 mM | 0.2047 mL | 1.0236 mL | 2.0472 mL | 5.1179 mL | |
| 25 mM | 0.1638 mL | 0.8189 mL | 1.6377 mL | 4.0943 mL | |
| 30 mM | 0.1365 mL | 0.6824 mL | 1.3648 mL | 3.4119 mL | |
| 40 mM | 0.1024 mL | 0.5118 mL | 1.0236 mL | 2.5590 mL | |
| 50 mM | 0.0819 mL | 0.4094 mL | 0.8189 mL | 2.0472 mL | |
| 60 mM | 0.0682 mL | 0.3412 mL | 0.6824 mL | 1.7060 mL | |
| 80 mM | 0.0512 mL | 0.2559 mL | 0.5118 mL | 1.2795 mL | |
| 100 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0236 mL |
Dioxybenzone Related Classifications
HY-B0966 Related Classifications
Powered by Bioz